HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir and raltegravir in the etravirine early access programme

MeSH terms

• Antiretroviral Therapy, Highly Active
• CD4 Lymphocyte Count
• Cohort Studies
• Darunavir
• Drug Administration Schedule
• Female
• HIV / genetics
• HIV / isolation & purification
• HIV Infections / drug therapy*
• HIV Infections / immunology
• HIV Infections / virology
• Humans
• Immunosuppression Therapy
• Male
• Middle Aged
• Nitriles
• Pyridazines / administration & dosage
• Pyridazines / therapeutic use*
• Pyrimidines
• Pyrrolidinones / administration & dosage
• Pyrrolidinones / therapeutic use*
• RNA, Viral / blood*
• Raltegravir Potassium
• Reverse Transcriptase Inhibitors / therapeutic use*
• Ritonavir / administration & dosage
• Ritonavir / therapeutic use*
• Sulfonamides / administration & dosage
• Sulfonamides / therapeutic use*
• Treatment Outcome